文献速递心脏核医学肿瘤 PET/CT

68Ga-FAPI PET显像可视化心力衰竭:从机制到临床

68Ga-FAPI PET visualize heart failure: from mechanism to clinic.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-10-21

本研究旨在探讨68Ga-FAPI PET/CT可视化心力衰竭过程中心肌纤维化和功能随时间变化的可行性。在大鼠模型中,心肌68Ga-FAPI摄取、FAP表达和心肌收缩力于首次ISO注射后第7天达峰,随后随纤维化加重而逐渐下降。在7例心力衰竭患者中,68Ga-FAPI PET显示心肌存在不同程度的摄取,且与13N-NH3心肌灌注并不完全匹配。

要点

  • 在ISO诱导的心力衰竭大鼠模型中,心肌68Ga-FAPI摄取和FAP表达于首次注射后第7天达峰,随后随纤维化加重逐渐下降。
  • 68Ga-FAPI PET可在体显示活跃的心肌纤维化,其摄取变化与心室壁运动随时间的变化相关。
  • 在7例心力衰竭患者中,心肌68Ga-FAPI摄取程度不一,且与13N-NH3心肌灌注并不完全匹配。

核心结论

  • 随着心力衰竭进展,68Ga-FAPI摄取在早期较高,随后逐渐下降;尽管研究为初步性质,结果提示68Ga-FAPI PET可用于显示活跃的心肌纤维化。
  • 活跃的心肌FAP表达之后出现心肌重构和纤维化;检测早期活跃的FAP表达可能有助于心力衰竭患者的治疗决策。

研究设计与样本

  • 建立异丙肾上腺素(ISO)诱导的心力衰竭大鼠模型(连续14天腹腔注射ISO),对实验组和对照组每周进行超声心动图和68Ga-FAPI PET/CT。
  • 大鼠心脏每周进行生物分布分析、放射自显影以及苏木精-伊红染色、FAP免疫荧光和Masson三色染色分析。
  • 每周采集大鼠血液,用酶联免疫吸附试验分析多种血浆指标。
  • 初步临床研究纳入7例心力衰竭患者,均接受13N-氨(NH3)灌注和68Ga-FAPI心脏PET显像。

主要发现

  • 动物实验中,心肌68Ga-FAPI摄取、FAP表达和心肌收缩力在首次ISO注射后第7天达峰;组织病理学检查仅见轻微纤维化改变。
  • 随时间推移,68Ga-FAPI摄取和心室壁运动下降,而心脏纤维化和心肌损伤程度逐渐增加。
  • 在人心力衰竭患者研究中,68Ga-FAPI PET显像发现心肌存在不同程度的68Ga-FAPI摄取,且与13N-NH3心肌灌注并不完全匹配。

临床怎么用

  • 原文结论指出,检测早期活跃的FAP表达可能有助于心力衰竭患者的治疗决策。

局限性

  • 作者在结论中写明「尽管研究为初步性质」(Although preliminary)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Heart failure (HF) is a chronic progressive clinical syndrome associated with structural and/or functional heart abnormalities. Active fibroblasts and ventricular remodelling play an essential role in HF progression. 68Ga-labelled fibroblast activation protein (FAP) inhibitor (68Ga-FAPI) binds to FAP. This study aimed to examine the feasibility of using 68Ga-FAPI positron emission tomography (PET)/computed tomography (CT) to visualize changes in cardiac fibrosis and function over time in the HF setting. METHODS: After establishing an isoproterenol (ISO)-induced HF rat model (14 consecutive days of intraperitoneal ISO injections), echocardiography and 68Ga-FAPI PET/CT were performed weekly in experimental and control groups. Rat hearts were examined weekly for biodistribution analysis; autoradiography; and haematoxylin and eosin, FAP immunofluorescence and Masson's trichrome staining analysis. Rat blood was sampled weekly for enzyme-linked immunosorbent assay analysis of various plasma indicators. A preliminary clinical study was also performed in seven HF patients who underwent both 13N-amino (NH3) perfusion and 68Ga-FAPI cardiac PET imaging. RESULTS: In the animal experiments, myocardial 68Ga-FAPI uptake, expression of FAP and myocardial contractility peaked on day 7 after the initial ISO injection. Only slight fibrotic changes were observed on histopathological examination. 68Ga-FAPI uptake and ventricular wall motion decreased over time as cardiac fibrosis and degree of myocardial injury gradually increased. In the human HF patient study, 68Ga-FAPI PET imaging identified varying degrees of 68Ga-FAPI uptake in the myocardium that did not precisely match with 13N-NH3 myocardial perfusion. CONCLUSION: As HF progresses, 68Ga-FAPI uptake is high in the early stages and then gradually decreases. Although preliminary, our findings suggest that 68Ga-FAPI PET can be used to demonstrate active myocardial fibrosis. Active myocardial FAP expression is followed by myocardial remodelling and fibrosis. Detection of early active FAP expression may assist treatment decision making in HF patients. CLINICAL TRIAL REGISTRATION: NCT04982458.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Song W, Zhang X, He S, et al. 68Ga-FAPI PET visualize heart failure: from mechanism to clinic. Eur J Nucl Med Mol Imaging. 2022. PMID: 36269382. doi:10.1007/s00259-022-05994-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。